163 related articles for article (PubMed ID: 17707958)
1. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.
Akporiaye ET; Bradley-Dunlop D; Gendler SJ; Mukherjee P; Madsen CS; Hahn T; Besselsen DG; Dial SM; Cui H; Trevor K
Vaccine; 2007 Sep; 25(39-40):6965-74. PubMed ID: 17707958
[TBL] [Abstract][Full Text] [Related]
2. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
Mukherjee P; Pathangey LB; Bradley JB; Tinder TL; Basu GD; Akporiaye ET; Gendler SJ
Vaccine; 2007 Feb; 25(9):1607-18. PubMed ID: 17166639
[TBL] [Abstract][Full Text] [Related]
3. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
4. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Greiner JW; Zeytin H; Anver MR; Schlom J
Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
[TBL] [Abstract][Full Text] [Related]
6. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.
Pietersz GA; Li W; Osinski C; Apostolopoulos V; McKenzie IF
Vaccine; 2000 Apr; 18(19):2059-71. PubMed ID: 10706970
[TBL] [Abstract][Full Text] [Related]
7. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
8. Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant.
Ruan J; Duan Y; Li F; Wang Z
Clin Exp Pharmacol Physiol; 2017 Jan; 44(1):71-78. PubMed ID: 27562635
[TBL] [Abstract][Full Text] [Related]
9. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.
Vang DP; Wurz GT; Griffey SM; Kao CJ; Gutierrez AM; Hanson GK; Wolf M; DeGregorio MW
J Vis Exp; 2013 Oct; (80):e50868. PubMed ID: 24300078
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model.
Wurz GT; Gutierrez AM; Greenberg BE; Vang DP; Griffey SM; Kao CJ; Wolf M; DeGregorio MW
J Transl Med; 2013 Mar; 11():64. PubMed ID: 23496860
[TBL] [Abstract][Full Text] [Related]
11. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
[TBL] [Abstract][Full Text] [Related]
12. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
13. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
[TBL] [Abstract][Full Text] [Related]
14. Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
Wu X; Yin Z; McKay C; Pett C; Yu J; Schorlemer M; Gohl T; Sungsuwan S; Ramadan S; Baniel C; Allmon A; Das R; Westerlind U; Finn MG; Huang X
J Am Chem Soc; 2018 Dec; 140(48):16596-16609. PubMed ID: 30398345
[TBL] [Abstract][Full Text] [Related]
15. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
[TBL] [Abstract][Full Text] [Related]
16. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
17. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
[TBL] [Abstract][Full Text] [Related]
18. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
20. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
